Video - Results from #50

ASCO GU 2022 VL

Search

Highlights In Urothelial Carcinoma at GU ASCO 2022 - Guru Sonpavde Details Guru Sonpavde joins Ashish Kamat to highlight key presentations showing promising data for new therapies in urothelial carcinoma from the ASCO GU 2022 annual meeting. Among the studies, he highlights the TROPHY-U-01 trial, the CheckMate 901 trial, the LEAP-011 study of first-line pembrolizumab with or without lenvatinib in patients with advanced urothelial carcinoma, the DS8201-A-U105 trial of tra...
Sacituzumab Govitecan in Combination With Pembrolizumab in Metastatic Urothelial Cancer – Petros Grivas Details Alicia Morgans and Petros Grivas discuss the TROPHY-U-01 data looking at patients who had progression of metastatic disease after exposure to platinum-based chemotherapy and who are now receiving sacituzumab govitecan in combination with a PDL-1 approach. Dr. Grivas gives a background on the combination of sacituzumab govitecan in combination with PD1 approaches. They also discuss the logistics of...
Next-Generation Sequencing - Discussing Results With Patients - Bishoy Faltas Details Alicia Morgans and Bishoy Faltas discuss the use of Next-Generation Sequencing (NGS) and how to use it in practice and communicate results to patients. Dr. Faltas gives a deep background on how NGS works and how it can be used to improve patient care. They also discuss why clinicians need to get familiar with the nuances of this sequencing to maximize the benefit of NGS. Because there are multiple...
Anticipated Data from Transformative Trials at ASCO GU 2022 - Oliver Sartor Details Alicia Morgans and Oliver Sartor discuss the upcoming American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium on Feb 17-20, 2022, and the data from key presentations in prostate cancer, bladder cancer, and kidney cancer. Biographies: A. Oliver Sartor, MD, Professor of Medicine and Medical Director, Tulane Cancer Center; C. E. and Bernadine Laborde Professor of Cancer Resear...